The stock of Sangamo Biosciences, Inc. (NASDAQ:SGMO) hit a new 52-week low and has $3.15 target or 10.00% below today’s $3.50 share price. The 7 months bearish chart indicates high risk for the $254.15M company. The 1-year low was reported on Nov, 2 by Barchart.com. If the $3.15 price target is reached, the company will be worth $25.42 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. The stock decreased 4.11% or $0.15 during the last trading session, hitting $3.5. About 388,436 shares traded hands. Sangamo Biosciences, Inc. (NASDAQ:SGMO) has declined 39.67% since March 31, 2016 and is downtrending. It has underperformed by 42.19% the S&P500.
Sangamo Biosciences, Inc. (NASDAQ:SGMO) Ratings Coverage
Out of 9 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 4 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 44% are positive. Sangamo Biosciences has been the topic of 12 analyst reports since August 8, 2015 according to StockzIntelligence Inc. On Friday, December 4 the stock rating was initiated by Wells Fargo with “Outperform”. Wedbush downgraded it to “Neutral” rating and $4 target price in Tuesday, November 1 report. The rating was reinitiated by Jefferies with “Buy” on Friday, October 23. The stock of Sangamo Biosciences, Inc. (NASDAQ:SGMO) has “Overweight” rating given on Saturday, August 8 by JP Morgan. Jefferies maintained it with “Buy” rating and $12 target price in Wednesday, September 2 report. The firm has “Buy” rating given on Wednesday, September 2 by Wedbush. On Friday, September 4 the stock rating was maintained by Cowen & Co with “Buy”. The rating was downgraded by Piper Jaffray to “Neutral” on Wednesday, October 19. The firm earned “Buy” rating on Thursday, September 3 by JP Morgan. Zacks downgraded the shares of SGMO in a report on Tuesday, September 8 to “Sell” rating.
According to Zacks Investment Research, “Sangamo BioSciences, Inc. is a leader in the development of novel transcription factors for the regulation of gene expression. Transcription factors are proteins that turn genes on or off by recognizing specific DNA sequences. The Universal Gene Recognition technology platform enables the engineering of a class of transcription factors known as zinc finger DNA binding proteins.”
Insitutional Activity: The institutional sentiment decreased to 0.81 in Q2 2016. Its down 0.57, from 1.38 in 2016Q1. The ratio worsened, as 20 funds sold all Sangamo Biosciences, Inc. shares owned while 42 reduced positions. 13 funds bought stakes while 37 increased positions. They now own 45.72 million shares or 4.72% less from 47.99 million shares in 2016Q1.
State Street Corporation last reported 0% of its portfolio in the stock. Oxford Asset Mngmt reported 77,442 shares or 0.02% of all its holdings. Blackrock Institutional Tru Na accumulated 0% or 1.75M shares. Teacher Retirement System Of Texas holds 0% of its portfolio in Sangamo Biosciences, Inc. (NASDAQ:SGMO) for 9,268 shares. First Republic Investment Management has 0% invested in the company for 19,500 shares. Moreover, Alliancebernstein L P has 0% invested in Sangamo Biosciences, Inc. (NASDAQ:SGMO) for 91,341 shares. Vanguard Grp, a Pennsylvania-based fund reported 2.69 million shares. Moreover, Princeton Alpha Management Lp has 0.03% invested in Sangamo Biosciences, Inc. (NASDAQ:SGMO) for 28,328 shares. Blackrock Inv Management Limited Liability Corp has invested 0% of its portfolio in Sangamo Biosciences, Inc. (NASDAQ:SGMO). Parametric Port Assoc Limited Liability Corporation holds 0% or 148,721 shares in its portfolio. Goldman Sachs Gru last reported 94,626 shares in the company. Sit Inc holds 26,725 shares or 0% of its portfolio. Numeric Invsts Limited Liability Company has 465,523 shares for 0.02% of their US portfolio. Ascend Capital Lc last reported 0.16% of its portfolio in the stock. Piermont last reported 0.23% of its portfolio in the stock.
More notable recent Sangamo Biosciences, Inc. (NASDAQ:SGMO) news were published by: Fool.com which released: “Why Sangamo Biosciences, Inc. Fell 29% Today” on August 04, 2016, also Prnewswire.com with their article: “Sangamo BioSciences Announces Third Quarter 2016 Conference Call and Webcast” published on October 19, 2016, Prnewswire.com published: “Sangamo BioSciences Announces Participation In Upcoming Scientific Conferences” on October 17, 2016. More interesting news about Sangamo Biosciences, Inc. (NASDAQ:SGMO) were released by: Prnewswire.com and their article: “Sangamo BioSciences Announces Retirement Of Edward Lanphier As President And …” published on June 01, 2016 as well as Prnewswire.com‘s news article titled: “Sangamo BioSciences Announces Second Quarter 2016 Conference Call and Webcast” with publication date: July 27, 2016.
SGMO Company Profile
Sangamo Biosciences Inc., incorporated on June 22, 1995, is a clinical-stage biopharmaceutical company. The Firm is focused on the research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. The Firm is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics, which are therapeutic products for the treatment of genetic disease. The Company’s ZFP Therapeutic, SB-728, a ZFP nuclease (ZFN)-modified autologous cell product for the treatment of Human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS), is the therapeutic application of its ZFN genome editing technology and is being evaluated in an ongoing Phase II study of ZFN-modified T-cells (SB-728-T-1101, Cohort 3) and a Phase I/II study of modified hematopoietic stem cells (SB-728mR-HSPC) in HIV-infected subjects. The Firm has preclinical programs in hemophilia A and other Lysergic acid diethylamide (LSDs), and research stage programs in other monogenic diseases, including certain central nervous system (CNS) disorders and cancer immunotherapy.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.